Abstract CT164: Efficacy and safety of osimertinib therapy in high-risk stage I EGFRm NSCLC after R0 resection(OSTAR): A phase II, prospective, single-arm study

Authors: Jiping Xie, Chen Chen, Bin Zhang, Changli Wang, Qiang Zhang, Zhenfa Zhang, Lei Zhang, Shengguang Wang, Xinyue Wang, Richeng Jiang, Dongsheng Yue

Published: 2025-04-25

DOI: 10.1158/1538-7445.am2025-ct164

Source: Full article